Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-Line Treatment for Advanced Hepatocellular Carcinoma: A Three-Armed Real-World Comparison.
Mahn R, Glüer OA, Sadeghlar F, Möhring C, Zhou T, Anhalt T, Monin MB, Kania A, Glowka TR, Feldmann G, Brossart P, Kalff JC, Schmidt-Wolf IGH, Strassburg CP, Gonzalez-Carmona MA. Mahn R, et al. Among authors: sadeghlar f. J Hepatocell Carcinoma. 2024 Jan 13;11:81-94. doi: 10.2147/JHC.S432948. eCollection 2024. J Hepatocell Carcinoma. 2024. PMID: 38239279 Free PMC article.
Programmed cell death protein 1 (PD-1)-inhibition in hepatocellular carcinoma (HCC): a single center experience.
Mahn R, Vogt A, Kupczyk P, Sadeghlar F, van Beekum K, Hüneburg R, Meyer C, Toma M, Ahmadzadehfar H, Essler M, Matthaei H, Lingohr P, Kalff JC, Strassburg CP, Gonzalez-Carmona MA. Mahn R, et al. Among authors: sadeghlar f. Scand J Gastroenterol. 2020 Sep;55(9):1057-1062. doi: 10.1080/00365521.2020.1794539. Epub 2020 Jul 21. Scand J Gastroenterol. 2020. PMID: 32692941
Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells.
Sadeghlar F, Vogt A, Mohr RU, Mahn R, van Beekum K, Kornek M, Weismüller TJ, Branchi V, Matthaei H, Toma M, Schmidt-Wolf IGH, Kalff JC, Strassburg CP, González-Carmona MA. Sadeghlar F, et al. Cancer Immunol Immunother. 2021 May;70(5):1451-1464. doi: 10.1007/s00262-020-02746-x. Epub 2020 Nov 12. Cancer Immunol Immunother. 2021. PMID: 33180184 Free PMC article.
Alpha-Fetoprotein- and CD40Ligand-Expressing Dendritic Cells for Immunotherapy of Hepatocellular Carcinoma.
Vogt A, Sadeghlar F, Ayub TH, Schneider C, Möhring C, Zhou T, Mahn R, Bartels A, Praktiknjo M, Kornek MT, Toma M, Schmidt-Wolf IGH, Branchi V, Matthaei H, Kalff JC, Strassburg CP, Gonzalez-Carmona MA. Vogt A, et al. Among authors: sadeghlar f. Cancers (Basel). 2021 Jul 5;13(13):3375. doi: 10.3390/cancers13133375. Cancers (Basel). 2021. PMID: 34282787 Free PMC article.
Multimodal and systemic therapy with cabozantinib for treatment of recurrent hepatocellular carcinoma after liver transplantation: A case report with long term follow-up outcomes.
Mahn R, Sadeghlar F, Bartels A, Zhou T, Weismüller T, Kupczyk P, Meyer C, Gaertner FC, Toma M, Vilz T, Knipper P, Glowka T, Manekeller S, Kalff J, Strassburg CP, Gonzalez-Carmona MA. Mahn R, et al. Among authors: sadeghlar f. Medicine (Baltimore). 2021 Sep 24;100(38):e27082. doi: 10.1097/MD.0000000000027082. Medicine (Baltimore). 2021. PMID: 34559100 Free PMC article.
First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis.
Möhring C, Feder J, Mohr RU, Sadeghlar F, Bartels A, Mahn R, Zhou T, Marinova M, Feldmann G, Brossart P, von Websky M, Matthaei H, Manekeller S, Glowka T, Kalff JC, Weismüller TJ, Strassburg CP, Gonzalez-Carmona MA. Möhring C, et al. Among authors: sadeghlar f. Front Oncol. 2021 Nov 10;11:717397. doi: 10.3389/fonc.2021.717397. eCollection 2021. Front Oncol. 2021. PMID: 34858809 Free PMC article.
Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy.
Gonzalez-Carmona MA, Möhring C, Mahn R, Zhou T, Bartels A, Sadeghlar F, Bolch M, Vogt A, Kaczmarek DJ, Heling DJ, Dold L, Nattermann J, Branchi V, Matthaei H, Manekeller S, Kalff JC, Strassburg CP, Mohr RU, Weismüller TJ. Gonzalez-Carmona MA, et al. Among authors: sadeghlar f. Sci Rep. 2022 Jan 19;12(1):1011. doi: 10.1038/s41598-021-04297-2. Sci Rep. 2022. PMID: 35046437 Free PMC article.
Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter?
Möhring C, Timotheou A, Mańczak A, Sadeghlar F, Zhou T, Mahn R, Bartels A, Monin M, Toma M, Feldmann G, Brossart P, Köksal M, Sarria GR, Giordano FA, Lingohr P, Jafari A, Kalff JC, Strassburg CP, Gonzalez-Carmona MA. Möhring C, et al. Among authors: sadeghlar f. J Cancer Res Clin Oncol. 2023 May;149(5):1849-1862. doi: 10.1007/s00432-022-04109-8. Epub 2022 Jun 28. J Cancer Res Clin Oncol. 2023. PMID: 35763109
Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate.
Zhou T, Mahn R, Möhring C, Sadeghlar F, Meyer C, Toma M, Kreppel B, Essler M, Glowka T, Matthaei H, Kalff JC, Strassburg CP, Gonzalez-Carmona MA. Zhou T, et al. Among authors: sadeghlar f. Front Oncol. 2022 Jul 25;12:933943. doi: 10.3389/fonc.2022.933943. eCollection 2022. Front Oncol. 2022. PMID: 35957899 Free PMC article.
25 results